A retrospective study assessing the factors associated with discontinuation of new hepatitis C drugs, second-generation direct-acting antivirals, in patients with chronic Hepatitis C
Latest Information Update: 16 Feb 2021
At a glance
- Drugs Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 16 Feb 2021 New trial record